Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: A pilot clinical trial

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Norell, Håkan ^a,b   Poschke, Isabel ^a   Charo, Jehad ^c   Wei, Wei Z ^d   Erskine, Courtney ^e   Piechocki, Marie P ^d   Knutson, Keith L ^e   Bergh, Jonas ^a   Lidbrink, Elisabet ^a   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d WAYNE STATE UNIVERSITY   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLASMID DNA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TRASTUZUMAB; CANCER ANTIBODY; DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HER2 PROTEIN, HUMAN; HLA ANTIGEN CLASS 2; INTERLEUKIN 2;

ABDOMINAL DRUG ADMINISTRATION; ACUTE TOXICITY; ADJUVANT THERAPY; ADULT; AGED; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOLOGICAL MONITORING; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; BREAST TUMOR; DOSE RESPONSE; GENETICS; IMMUNOLOGY; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PLASMID; T LYMPHOCYTE; VACCINATION;

ADULT; AGED; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CANCER VACCINES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNITY, HUMORAL; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM METASTASIS; PILOT PROJECTS; PLASMIDS; RECEPTOR, ERBB-2; T-LYMPHOCYTES; VACCINATION;

EID: 77953036244     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-53     Document Type: Article

References (55)

1. Seliger B, Rongcun Y, Atkins D, Hammers S, Huber C, Storkel S, Kiessling R. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer 2000, 87:349-359. 10.1002/1097-0215(20000801)87:3<349::AID-IJC7>3.0.CO;2-O, 10897039.
2. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 2000, 103:57-75.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
4. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274. 10.1200/JCO.2005.04.173, 15911866.
5. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
6. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36. 10.1016/S0140-6736(07)60028-2, 17208639.
7. Baselga J. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. Ann Oncol 2008, 19(Suppl 7):vii281-288. 10.1093/annonc/mdn433, 18790967.
8. Park BH, Davidson NE. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?. Cancer Cell 2007, 12:297-299. 10.1016/j.ccr.2007.10.004, 17936554.
9. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
10. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002, 85:101-144. full_text, 12374283.
11. Wei WZ, Jacob J, Radkevich-Brown O, Whittington P, Kong YC. The "A, B and C" of Her-2 DNA vaccine development. Cancer Immunol Immunother 2008, 57:1711-1717. 10.1007/s00262-008-0464-y, 18273615.
12. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody Trastuzumab Enhances Cytolytic Activity of Class I-restricted HER2-specific T Lymphocytes Against HER2-overexpressing Tumor Cells. Cancer Res 2002, 62:2244-2247.
13. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci 1997, 60:163-172. 10.1016/S0024-3205(96)00502-4, 9000640.
14. Corr M, Lee DJ, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996, 184:1555-1560. 10.1084/jem.184.4.1555, 2192808, 8879229.
15. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-854. 10.1038/nm0897-849, 9256274.
16. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8:108-120. 10.1038/nrc2326, 18219306.
17. Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 2008, Chapter 20. Unit 20 29 21-20 29-10.
18. Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006, 6:8. 1976276, 16626110.
19. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24:4582-4585. 10.1016/j.vaccine.2005.08.027, 16188351.
20. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9:776-788. 10.1038/nrg2432, 18781156.
21. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA Vaccines Encoding Full-Length or Truncated Neu Induce Protective Immunity against Neu-expressing Mammary Tumors. Cancer Res 1998, 58:1965-1971.
22. Charo J, Ciupitu AM, Le Chevalier De Preville A, Trivedi P, Klein G, Hinkula J, Kiessling R. A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J Immunol 1999, 163:5913-5919.
23. Charo J, Sundback M, Geluk A, Ottenhoff T, Kiessling R. DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. Hum Gene Ther 2001, 12:1797-1804. 10.1089/104303401750476285, 11560772.
24. Lin C-C, Chou C-W, Shiau A-L, Tu C-F, Ko T-M, Chen Y-L, Yang B-C, Tao M-H, Lai M-D. Therapeutic HER2/Neu DNA Vaccine Inhibits Mouse Tumor Naturally Overexpressing Endogenous Neu. Mol Ther 2004, 10:290-301. 10.1016/j.ymthe.2004.05.015, 15294176.
25. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999, 81:748-754. 10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6, 10328228.
26. Messerle K, Schlegel J, Hynes NE, Groner B. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. Mol Cell Endocrinol 1994, 105:1-10. 10.1016/0303-7207(94)90029-9, 7821711.
27. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004, 91:688-694. 2364780, 15280930.
28. Lindencrona JA, Preiss S, Kammertoens T, Schuler T, Piechocki M, Wei WZ, Seliger B, Blankenstein T, Kiessling R. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004, 109:259-264. 10.1002/ijc.11654, 14750178.
29. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999, 5:1289-1297.
30. Reece JC, Geysen HM, Rodda SJ. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. J Immunol 1993, 151:6175-6184.
31. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001, 107:477-484. 10.1172/JCI11752, 199268, 11181647.
32. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006, 24:4254-4261. 10.1200/JCO.2006.05.9311, 16908932.
33. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, et al. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res 2010, 16:825-834. 10.1158/1078-0432.CCR-09-2781, 20103660.
34. Knutson K, Beebe M, Vielhauer G, Disis ML, Ishioka G. High affinity MHC class II epitopes can be accurately predicted with publicly available algorithms [abstract #5165]. Proc Amer Assoc Cancer Res 2005, 46.
35. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 2007, 13:5133-5143. 10.1158/1078-0432.CCR-07-0507, 17785568.
36. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002, 20:2624-2632. 10.1200/JCO.2002.06.171, 12039923.
37. Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003, 21:3965-3971. 10.1200/JCO.2003.12.109, 14507946.
38. Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 2009, 58:653-664. 10.1007/s00262-008-0587-1, 18820911.
39. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 2004, 64:215-220. 10.1158/0008-5472.CAN-2522-2, 14729627.
40. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004, 108:71-77. 10.1002/ijc.11497, 14618618.
41. Benavides LC, Gates JD, Carmichael MG, Patel R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009, 15:2895-2904. 10.1158/1078-0432.CCR-08-1126, 19351776.
42. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009, 27:4685-4692. 10.1200/JCO.2008.20.6789, 19720923.
43. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol 2004, 22:1916-1925. 10.1200/JCO.2004.09.005, 15143085.
44. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001, 61:880-883.
45. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. J Immunol 2004, 173:2288-2296.
46. Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005, 174:4228-4236.
47. Lemoine FM, Cherai M, Giverne C, Dimitri D, Rosenzwajg M, Trebeden-Negre H, Chaput N, Barrou B, Thioun N, Gattegnio B, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol 2009, 35:569-581. 10.3892/ijo_00000368, 19639177.
48. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007, 18:226-232. 10.1093/annonc/mdl158, 17116643.
49. Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007, 5:42. 10.1186/1479-5876-5-42, 2042490, 17822557.
50. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-3367.
51. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990, 5:953-962.
52. Ewer MS, Lenihan DJ. Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?. Nat Clin Pract Oncol 2008, 5:192-193. 10.1038/ncponc1045, 18212766.
53. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008, 14:797-803. 10.1158/1078-0432.CCR-07-1448, 18245541.
54. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, et al. Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol 2009, 27:1999-2006. 10.1200/JCO.2008.19.6618, 19289619.
55. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743. 10.1056/NEJMoa064320, 17192538.